WallStSmart

Eli Lilly and Company (LLY)vsRecursion Pharmaceuticals Inc (RXRX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 126618% more annual revenue ($86.46B vs $68.23M). LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16

RXRX

Hold

35

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -0.84

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

RXRX3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
258.5%10/10

Revenue surging 258.5% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.7x2/10

Trading at 31.7x book value

RXRX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-54.6%2/10

ROE of -54.6% — below average capital efficiency

Free Cash FlowQuality
$-77.81M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bull Case : RXRX

The strongest argument for RXRX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 258.5% demonstrates continued momentum.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Bear Case : RXRX

The primary concerns for RXRX are EPS Growth, Profit Margin, Return on Equity.

Key Dynamics to Monitor

LLY profiles as a growth stock while RXRX is a hypergrowth play — different risk/reward profiles.

RXRX carries more volatility with a beta of 1.15 — expect wider price swings.

RXRX is growing revenue faster at 258.5% — sustainability is the question.

LLY generates stronger free cash flow (8.2B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (74/100 vs 35/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Recursion Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.

Want to dig deeper into these stocks?